Non-CETP Novel Targets and New Drug Therapies Targeting HDL


Non-CETP Novel Targets and New Drug Therapies Targeting HDL

Topic: Cardiology
Relevant Terms: Novel Drug Therapies
Primary Audience: Cardiologists; endocrinologists; internists; lipidologists; primary care physicians; physician assistants; nurse practitioners; pharmacists; registered nurses; and registered dietitians
Launch Date: 18-Dec-12
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discuss emerging HDL- based therapeutics; their promise and potential pitfalls
  2. Identify novel HDL therapies in development and analyze their role in reversing atherosclerosis
  3. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    Michael H. Davidson, MD, FNLA *
    Clinical Professor
    Director of Preventive Cardiology
    The University of Chicago Pritzker School of Medicine
    Chicago, IL
    Danielle Duffy, MD
    Assistant Professor of Medicine
    Division of Cardiology
    Jefferson Medical College and Thomas Jefferson University
    Philadelphia, PA
    Program Overview
    The Translation of HDL Science Curriculum Slide Library consists of 6 (six) interactive slide lecture note modules that convey the latest evidence and research on HDL and residual risk epidemiology, HDL metabolism, HDL functionality and subfractions, existing HDL raising therapies, novel targets of therapy and therapies in development.  As a key component of the National Lipid Association's HDL Science Core Curriculum, the NLA HDL Slide Library provides high-value slide presentation materials with state of the art, peer-reviewed content developed by International experts in lipidology and HDL research.  These core slides provide the medical community with NLA-endorsed content for both teaching and learning purposes that helps to efficiently translate the core scientific principles of the HDL curriculum to clinical practice.
    This slide module will highlight the various drug therapies in development for targeting HDL The module will present the differences amongst the various therapeutic options and demonstrate that the overarching goal of all novel HDL therapeutics is the prevention of cardiovascular events.

    Activity Format
    Enduring Internet
    There is no fee associated with this activity

    Type of Activity

    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 55% or better and the completion of the activity evaluation. If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by December 18, 2013.
    For Pharmacists, transcript information will be available at within 4 weeks.
    Commercial Support
    This activity is supported by an educational grant from Abbott Laboratories, Genentech, USA, and Merck and Co., Inc.
    Credit Designation
    CME credit provided by the National Lipid Association
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
    CE Credit provided by Postgraduate Institute for Medicine

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-256-H01-P (Knowledge)
    Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hours (0.01 CEUs) of the Accreditation Council for Pharmacy Education.
    This educational activity for 1 contact hours is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
    This program has been approved by the Commission on Dietetic Registration for 1.0 CPEUs. Contact Postgraduate Institute for Medicine ( for details.

    Davidson, Michael
    Advisory Board
    Amgen; AstraZeneca; Merck & Co., Inc.;  Sanofi Aventis
    Duffy, Danielle
    Contracted Research
    Forest Laboratories; Roche/ Genentech; Abbott Laboratories
    Nothing to disclose
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.